BRAF mutations in papillary carcinomas of the thyroid

被引：236

作者：

Fukushima, T

Suzuki, S

Mashiko, M

Ohtake, T

Endo, Y

Takebayashi, Y

Sekikawa, K

Hagiwara, K

Takenoshita, S

机构：

[1] Fukushima Med Univ, Dept Surg, Fukushima 9601295, Japan

[2] Saitama Med Sch, Dept Resp Med, Moroyama, Saitama 3500495, Japan

来源：

ONCOGENE | 2003年 / 22卷 / 41期

关键词：

BRAF; RAS; papillary carcinoma of the thyroid; follicular carcinoma of the thyroid; MAP kinase pathway;

D O I：

10.1038/sj.onc.1206739

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

BRAF is a serine/threonine kinase that receives a mitogenic signal from RAS and transmits it to the MAP kinase pathway. Recent studies have reported that mutations of the BRAF gene were detected with varying frequencies in several cancers, notably more than 60% in melanoma. We analysed mutations of BRAF and RAS genes in 100 cases of thyroid carcinoma to investigate genetic aberrations in the RAS/RAF/MEK/MAP kinase pathway. BRAF mutations were detected exclusively in papillary carcinomas ( 40 in 76 cases: 53%), and were exclusively V599E, a mutation frequently observed in other carcinomas. NRAS mutation was observed in six cases (6%), all in histological types other than papillary carcinoma, and was exclusively Q61R. No mutations were found in KRAS or HRAS. Our results suggest that BRAF mutations may play a critical role in the carcinogenesis of papillary carcinoma of the thyroid.

引用

页码：6455 / 6457

页数：3